Skip To Main Content
For US Healthcare Professionals

Diabetic Macular Edema (DME)

How VABYSMO may help in wet AMD

Man carrying child

VABYSMO improves vision quickly and gives you a chance to go 1-4 months injection-free*

*After 4 monthly starting doses.

VABYSMO IMPROVED VISION QUICKLY

Clinical studies showed people on VABYSMO had vision gains similar to those on aflibercept

Clinical studies showed people on VABYSMO had vision gains similar to those on aflibercept

On average, people gained and maintained 6 letters on an eye chart in 1 year (chart)

On average, people gained and maintained 6 letters on an eye chart in 1 year

vs aflibercept, with average gains of 6 letters.

VABYSMO helped people gain some vision back quickly after their first treatment. On average, people gained 5 letters at 1 month, similar to aflibercept.

The safety & effectiveness of VABYSMO were assessed in 2 clinical studies vs aflibercept with 1329 people with wet AMD. 

After 4 monthly starting doses, 664 people received VABYSMO every 2, 3, or 4 months based on their response to treatment at months 5 and 6. In comparison, 662 people received aflibercept every 2 months (after 3 starting doses). Longer dosing schedules were not studied for these patients.

WITH VABYSMO, YOUR NEXT TREATMENT COULD BE MONTHS AWAY

Approved 1-4 months (graphic)
Approved 1-4 months (graphic)

After 4 monthly doses, your Retina Specialist may want to scan your eye, or give you a vision test. These will help determine if you can extend to 2, 3, or 4 month dosing.

2-3-4 months between injections (graphic)

Although some patients from the clinical trials went 3-4 months between injections and did well, this may not be the experience of all patients. Your Retina Specialist may evaluate your disease differently from the methods used in our trials. 

After 4 monthly doses, 664 people received VABYSMO every 2, 3, or 4 months based on their response to treatment at months 5 and 6. 

In comparison, 662 people received aflibercept every 2 months after 3 starting doses (longer dosing schedules were not studied for people on aflibercept).

It’s possible to go 1-4 months injection-free‖

‖After 4 monthly starting doses.

It’s possible to go 1-4 months injection-free‖

‖After 4 monthly starting doses.

We’re here to help

The Genentech Ophthalmology Support Line makes it easy for you to quickly access the information and support you need.

Just call (833) EYE-GENE/(833) 393-4363 and one of our representatives will be with you soon. Our representatives are available Monday-Friday, 9 am - 8 pm ET. 

Sign up for VABYSMO Patient Support and receive the VABYSMO Patient Support Kit.

SIGN UP FOR SUPPORT

There may be options to help you afford VABYSMO. Find out what assistance you might be eligible for.

DISCOVER FINANCIAL SUPPORT

We’re here to help

Sign up for VABYSMO Patient Support and receive the VABYSMO Patient Support Kit.

SIGN UP FOR SUPPORT

There may be options to help you afford VABYSMO. Find out what assistance you might be eligible for.

DISCOVER FINANCIAL SUPPORT

The Genentech Ophthalmology Support Line makes it easy for you to quickly access the information and support you need.

Just call (833) EYE-GENE/(833) 393-4363 and one of our representatives will be with you soon. Our representatives are available Monday-Friday, 9 am - 8 pm ET. 

What is VABYSMO?

VABYSMO (faricimab-svoa) is a prescription medicine given by injection into the eye, used to treat adults with Neovascular (Wet) Age-related Macular Degeneration (AMD) and Diabetic Macular Edema (DME).

Do not receive VABYSMO if you:

  • have an infection in or around your eye. 
  • have active swelling around your eye that may include pain and redness. 
  • are allergic to VABYSMO or any of the ingredients in VABYSMO.

What is the most important information I should know about VABYSMO?

  • Injections like the one for VABYSMO can cause an eye infection (endophthalmitis) or separation of layers of the retina (retinal detachment). Call your healthcare provider right away if you have increasing eye pain, vision loss, sensitivity to light, or redness in the white of the eye.
  • VABYSMO may cause a temporary increase in pressure in the eye (intraocular pressure), which occurs 60 minutes after the injection. 
  • Although not common, VABYSMO patients have had serious, sometimes fatal, problems related to blood clots, such as heart attacks or strokes (thromboembolic events). In clinical studies for wet AMD during the first year, 7 out of 664 patients treated with VABYSMO reported such an event. In DME studies during the first year, 25 out of 1,262 patients treated with VABYSMO reported such an event.

Before receiving VABYSMO, tell your healthcare provider about all of your medical conditions, including if you:

  • Are pregnant or plan to become pregnant. Based on how VABYSMO interacts with your body, there may be a potential risk to your unborn baby. You should use birth control before your first injection, during your treatment with VABYSMO, and for 3 months after your last dose of VABYSMO. 
  • Are breastfeeding or plan to breastfeed. It is not known if VABYSMO passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you receive VABYSMO.
  • Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What should I avoid while receiving VABYSMO? 

  • Your vision may be impaired after receiving an eye injection or after an eye exam; do not drive or use machinery until your vision has recovered sufficiently.  

What are the most common side effects with VABYSMO?

  • The most common side effect with VABYSMO was blood on the white of the eye (conjunctival hemorrhage).
  • These are not all the possible side effects of VABYSMO. 

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Genentech at 1-888-835-2555. 

Please see the VABYSMO full Prescribing Information for additional Important Safety Information.